Singapore Firm Abandons Plans for Stem Cell Therapies
By Dennis Normile,
Science
| 07. 20. 2007
In a sign that hopes for quick medical benefits from stem cells are fading, ES Cell International (ESI)--a company established with fanfare in Singapore 7 years ago--is halting work on human embryonic stem (hES) cell therapies. Investors lost interest because "the likelihood of having products in the clinic in the short term was vanishingly small," says Alan Colman, a stem cell pioneer who until last month was ESI's chief executive.
ESI's setback may dampen investors' enthusiasm for stem cell therapies, says Robert Lanza, vice president for R&D at Advanced Cell Technology in Worcester, Massachusetts: "What the field badly needs is one or two success stories."
Colman, a member of the team that cloned the sheep Dolly, will become head of the Singapore Stem Cell Consortium, which funds research at institutes affiliated with Singapore's Agency for Science, Technology and Research (A*STAR) and also offers grants. He will also set up a lab at A*STAR's Institute of Molecular and Cell Biology. Most of the 24 scientists working on hES cell therapies at ESI will continue their research with "more secure government funding"...
Related Articles
By Nicholas Wade, The New York Times | 04.30.2026
“J. Craig Venter” via Wikimedia Commons licensed under CC by 2.5
J. Craig Venter, a scientist and entrepreneur who raced to decode the human genome, died on Wednesday in San Diego. He was 79.
His death was announced by...
By Susan Dominus, The New York Times Magazine | 04.27.2026
Why are babies born young? The most natural phenomenon on earth is actually hard to explain — at least on a cellular level. Consider this problem: The components of conception are old. When a woman gets pregnant, she has...
By Rob Stein, NPR | 04.23.2026
The Food and Drug Administration approved the first gene therapy to restore hearing for people who were born deaf.
The decision, while only immediately affecting people born with a very rare form of genetic deafness, is being hailed as...
By Emile P. Torres, Truthdig | 04.27.2026
The CEO of OpenAI, Sam Altman, is on a messianic mission to bring about the singularity, the moment at which artificial intelligence begins to self-improve. If AI is smart enough to build the next generation of even smarter AI...
